Literature DB >> 15355925

The role of hyperthermia in regional alkylating agent chemotherapy.

Omar I Abdel-Wahab1, Elizabeth Grubbs, Benjamin L Viglianti, Tsung-Yen Cheng, Tomio Ueno, SaeHee Ko, Zahid Rabbani, Simon Curtis, Scott K Pruitt, Mark W Dewhirst, Doug S Tyler.   

Abstract

The role of hyperthermia during regional alkylating agent chemotherapy is controversial. The aim of this study was to determine the exact contribution of hyperthermia to tumor response during isolated limb infusion with l-phenylalanine mustard. Rats bearing rodent fibrosarcoma on the hindlimb underwent isolated limb infusion with saline, saline plus heat, l-phenylalanine mustard, l-phenylalanine mustard under conditions of normothermia, or l-phenylalanine mustard plus hyperthermia. Heat was administered locally using an in-line hot water circulation loop. Treatment with l-phenylalanine mustard at a concentration of 15 or 50 micrograms/mL was ineffective at producing tumor growth delay (P = 0.24 and 0.41, respectively). Furthermore, thermal enhancement of l-phenylalanine mustard activity was not seen at 15 micrograms/mL. However, administration of high-dose l-phenylalanine mustard, 50 micrograms/mL, with increasing amounts of heat yielded increasing tumor growth delay, increased regressions, and decreased proliferative index. Although l-phenylalanine mustard infusion under normothermia yielded a tumor growth delay of 7.1 days, combination l-phenylalanine mustard + hyperthermia treatment produced tumor growth delay of 27.0 days (P < 0.01; with two of five animals showing a complete response). Four hours after isolated limb infusion, 50.9% of cells in tumor treated with l-phenylalanine mustard + hyperthermia experienced apoptosis, whereas only 18.1, 16, and 4.4% of cells underwent apoptosis after treatment with l-phenylalanine mustard, saline + hyperthermia, or saline. The mean concentration of l-phenylalanine mustard within tumor relative to perfusate following isolated limb infusion was found to be similar among all groups at 0.023, 0.025, and 0.032 in animals undergoing isolated limb infusion with l-phenylalanine mustard, l-phenylalanine mustard + normothermia, and l-phenylalanine mustard + hyperthermia, respectively. These data indicate a synergistic cytotoxic effect of l-phenylalanine mustard + hyperthermia in isolated limb infusion, which is not attributable to enhanced tumor drug uptake.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15355925     DOI: 10.1158/1078-0432.CCR-04-0096

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

Review 1.  Regional treatment strategies for in-transit melanoma metastasis.

Authors:  Ryan S Turley; Amanda K Raymond; Douglas S Tyler
Journal:  Surg Oncol Clin N Am       Date:  2011-01       Impact factor: 3.495

Review 2.  Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Authors:  Dale Han; Georgia M Beasley; Douglas S Tyler; Jonathan S Zager
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-10-07       Impact factor: 4.481

3.  Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

Authors:  N McMahon; T Y Cheng; G M Beasley; I Spasojevic; W Petros; C K Augustine; P Zipfel; J C Padussis; G Sanders; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2009-01-30       Impact factor: 5.344

4.  Quinacrine for extremity melanoma in a mouse model of isolated limb perfusion (ILP).

Authors:  Minhyung Kim; Asher B Blum; Michelle L Haslinger; Michael J Donahue; Daniel T Fisher; Joseph J Skitzki; Il Young Park
Journal:  Surg Today       Date:  2014-07-08       Impact factor: 2.549

5.  Systemic anti-tumour effects of local thermally sensitive liposome therapy.

Authors:  Benjamin L Viglianti; Mark W Dewhirst; R J Boruta; Ji-Young Park; Chelsea Landon; Andrew N Fontanella; Jing Guo; Ashley Manzoor; Christina L Hofmann; Gregory M Palmer
Journal:  Int J Hyperthermia       Date:  2014-08-28       Impact factor: 3.914

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.